Trial · NCT01298141
Adverse events237
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 237
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Replagal (Agalsidase Alfa) | 11 | 167 | 25 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Replagal (Agalsidase Alfa) | 45 | 167 | 68 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Replagal (Agalsidase Alfa) | 46 | 167 | 63 |
| other | Joint swelling | Musculoskeletal and connective tissue disorders | Replagal (Agalsidase Alfa) | 14 | 167 | 17 |
| other | Muscle spasms | Musculoskeletal and connective tissue disorders | Replagal (Agalsidase Alfa) | 22 | 167 | 30 |
| other | Muscular weakness | Musculoskeletal and connective tissue disorders | Replagal (Agalsidase Alfa) | 10 | 167 | 12 |
| other | Musculoskeletal pain | Musculoskeletal and connective tissue disorders | Replagal (Agalsidase Alfa) | 23 | 167 | 29 |
| other | Myalgia | Musculoskeletal and connective tissue disorders | Replagal (Agalsidase Alfa) | 21 | 167 | 22 |
| other | Neck pain | Musculoskeletal and connective tissue disorders | Replagal (Agalsidase Alfa) | 14 | 167 | 14 |
| other | Osteoarthritis | Musculoskeletal and connective tissue disorders | Replagal (Agalsidase Alfa) | 12 | 167 | 12 |
| other | Pain in extremity | Musculoskeletal and connective tissue disorders | Replagal (Agalsidase Alfa) | 34 | 167 | 49 |
| other | Flushing | Vascular disorders | Replagal (Agalsidase Alfa) | 9 | 167 | 49 |
| other | Hypertension | Vascular disorders | Replagal (Agalsidase Alfa) | 17 | 167 | 22 |
| other | Hypotension | Vascular disorders | Replagal (Agalsidase Alfa) | 17 | 167 | 23 |
| other | Ear pain | Ear and labyrinth disorders | Replagal (Agalsidase Alfa) | 11 | 167 | 11 |
| other | Tinnitus | Ear and labyrinth disorders | Replagal (Agalsidase Alfa) | 17 | 167 | 17 |
| other | Vertigo | Ear and labyrinth disorders | Replagal (Agalsidase Alfa) | 23 | 167 | 26 |
| other | Vision blurred | Eye disorders | Replagal (Agalsidase Alfa) | 16 | 167 | 19 |
| other | Abdominal discomfort | Gastrointestinal disorders | Replagal (Agalsidase Alfa) | 13 | 167 | 14 |
| other | Abdominal pain | Gastrointestinal disorders | Replagal (Agalsidase Alfa) | 29 | 167 | 50 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01298141/events